Vivos Therapeutics (VVOS) Shares Outstanding (Weighted Average) (2019 - 2026)

Vivos Therapeutics (VVOS) has 8 years of Shares Outstanding (Weighted Average) data on file, last reported at $14.6 million in Q1 2026.

• Quarterly Shares Outstanding (Weighted Average) rose 70.26% year-over-year to $14.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.6 million (up 70.26% YoY) and the FY2025 annual result came in at $10.3 million, up 104.66% from the prior year.
• Shares Outstanding (Weighted Average) rose to $14.6 million in Q1 2026 per VVOS's latest filing, from $10.3 million in the prior quarter.
• Across five years, Shares Outstanding (Weighted Average) topped out at $24.8 million in Q1 2023 and bottomed at $849446.0 in Q3 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $5.0 million (2024), against an average of $8.3 million.
• The widest annual swing landed in 2022, when Shares Outstanding (Weighted Average) sank 100.0%; it then jumped 311.67% in 2024.
• Tracing VVOS's Shares Outstanding (Weighted Average) over 5 years: stood at $920592.0 in 2022, then surged by 32.46% to $1.2 million in 2023, then jumped by 311.67% to $5.0 million in 2024, then jumped by 104.66% to $10.3 million in 2025, then jumped by 42.44% to $14.6 million in 2026.
• Per Business Quant, the three latest VVOS Shares Outstanding (Weighted Average) figures stand at $14.6 million (Q1 2026), $10.3 million (Q4 2025), and $11.0 million (Q3 2025).

Peer Comparison